The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Managing cytopenias following JAK inhibitor treatment & achieving true disease modification in MF
Aaron Gerds, MD, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, addresses the challenges and management of complications associated with JAK inhibitor therapy for myelofibrosis (MF), including anemia and thrombocytopenia. Dr Gerds comments on the need to use drugs that target anemia when delivering JAK inhibitor therapy and also explores the goal of achieving true disease modification in MF. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
